Related Experiment Videos
Warfarin for dilated cardiomyopathy: a bloody tough pill to swallow?
J Tsevat1, M H Eckman, R A McNutt
1Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts 02111.
Insights
Anticoagulant therapy for dilated cardiomyopathy may improve quality-adjusted life expectancy by preventing pulmonary embolization. However, the benefits must be weighed against the lifestyle impact of long-term warfarin treatment.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Current recommendations advocate long-term anticoagulation for dilated cardiomyopathy to prevent systemic embolization.
- No clinical trials have verified anticoagulation's effectiveness in preventing systemic embolization in these patients.
- Quality of life considerations for long-term warfarin therapy are often overlooked.
Purpose of the Study:
- To analyze the benefits and risks of long-term anticoagulation in patients with dilated cardiomyopathy.
- To evaluate the impact of anticoagulation on quality-adjusted life expectancy.
Main Methods:
- Decision analysis was employed to model outcomes for patients aged 35-75 with dilated cardiomyopathy.
- Sensitivity analysis was performed to assess the influence of warfarin therapy's disutility.
Main Results:
- Anticoagulant therapy is projected to increase quality-adjusted life expectancy by 76–128 days, varying with patient age.
- The primary benefit of anticoagulation appears to be the prevention of pulmonary embolization, not systemic embolization.
- The overall outcome is sensitive to the disutility associated with long-term warfarin therapy.
Conclusions:
- While anticoagulation is likely beneficial for many dilated cardiomyopathy patients, lifestyle changes must be considered.
- The decision to anticoagulate should balance potential survival gains against the burdens of long-term warfarin therapy.
- For some individuals, the sacrifices associated with anticoagulation may outweigh the clinical benefits.
Abstract:
Although current recommendations for the treatment of dilated cardiomyopathy include long-term anticoagulation to diminish the likelihood of systemic embolization, there have been no clinical trials examining the effectiveness of anticoagulation in preventing systemic embolization in these patients. Furthermore, those recommendations do not address the issue of the quality of life associated with long-term warfarin therapy. Using decision analysis, the authors examined the benefits and risks of long-term anticoagulation for patients 35 to 75 years of age who have dilated cardiomyopathy. The results show that anticoagulant therapy increases quality-adjusted life expectancy by 76 to 128 days, depending on the patient's age. Sensitivity analysis, however, demonstrates that the outcome is dependent on the disutility associated with long-term warfarin therapy. Interestingly, anticoagulation exerts most of its benefit by preventing pulmonary embolization, not systemic embolization. The authors conclude that the current recommendation to anticoagulate these patients, although probably correct for many patients, should take into consideration the change in lifestyle imposed by long-term anticoagulant therapy. For some patients, the benefit may not outweigh the sacrifice.